The bioprocess bags market size was exhibited at USD 4.25 Billion in 2024 and is projected to hit around USD 19.42 Billion by 2034, growing at a CAGR of 16.41% during the forecast period 2024 to 2034.
Report Coverage | Details |
Market Size in 2025 | USD 4.95 Billion |
Market Size by 2034 | USD 19.42 Billion |
Growth Rate From 2024 to 2034 | CAGR of 16.41% |
Base Year | 2024 |
Forecast Period | 2024-2034 |
Segments Covered | Type, Workflow, End user, Region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Covered | North America, Europe, Asia Pacific, Latin America, MEA |
Key Companies Profiled | Thermo Fisher Scientific Inc.; Sartorius AG, Danaher Corporation; Merck KGaA; Saint-Gobain; Corning Incorporated; Entegris; Meissner Filtration Products, Inc.; PROAnalytics, LLC; CellBios Healthcare & Lifesciences Pvt Ltd. |
The market is being driven by several factors such as, the growing demand for biopharmaceuticals, including monoclonal antibodies and vaccines, advancements in bioprocess technology, such as single-use systems and disposable bioprocess bags, and the increasing adoption of modular manufacturing. Furthermore, the rising demand for personalized medicine is leading to the development of new biologics and other complex therapeutics, which require specialized manufacturing processes that can benefit from bioprocess bags.
The COVID-19 pandemic has had a significant impact on the bioprocess bags market. The market is primarily driven by the biopharmaceutical industry, which has seen increased demand due to the development of COVID-19 vaccines and other advanced therapies. The production of vaccines and protein therapeutics requires bioprocess bags for the production, storage and transport of biologics, which has led to a surge in demand for these bags. Furthermore, the pandemic has also resulted in a shift in focus towards single-use bioprocess bags. They are preferred over traditional stainless-steel tanks due to their low risk of contamination, increased flexibility, cost effectiveness, and ease of use.
For instance, in February 2022, Dow, Südpack Medica, and Sartorius have joined forces to produce bioprocessing bags that are crucial for manufacturing and transporting vaccines in the global fight against COVID-19. The collaboration involves the production of sterile bioreactor bags made from multi-layered film that can hold up to 2,000 liters. These bags are designed for optimized stirring and high oxygen transfer, making them suitable for mammalian cell culture processes that are microcarrier-based or require high cell density.
These bags are made of flexible plastic materials and are designed to withstand the rigorous demands of the biopharmaceutical manufacturing process. They are available in different sizes and configurations, depending on the specific needs of the manufacturer. The market is expected to see significant growth due to the rising demand for biopharmaceuticals. The demand for biopharmaceuticals is increasing due to several factors, including an aging population, the prevalence of chronic diseases, and a growing demand for personalized medicine. As a result, the bioprocess bags market is expected to grow significantly over the coming years. For instance, in 2022, approximately 340 biologics were approved by the Food and Drug Administration.
Furthermore, the rising outsourcing activity by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) is expected to drive the demand for bioprocess bags. CMOs and CROs are companies that provide manufacturing and research services to pharmaceutical and biotech companies. The biopharma giants are increasingly outsourcing their bioprocessing activities, including the production, storage, and transportation of biologics, to third-party service providers. Bioprocessing bags are an essential component of biologics manufacturing, and their demand is expected to grow as more companies outsource their bioprocessing activities. For instance, in July 2021, Pall Corporation announced a contract with Exothera S.A. that is valued at more than $7 million. This new agreement is intended to create a suspension-based manufacturing platform capable of producing up to 2000L of product. The platform will utilize a range of technologies including Allegro STR single-use bioreactors to produce various viral vectors used in gene therapies and viral vector-based vaccines.
The 2D bioprocess bags held the highest market share of over 46.28% in 2024. This is due to the increasing demand for biopharmaceuticals and cell therapies. As the prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders continues to rise, there is a growing need for innovative and effective treatments. Biopharmaceuticals offer a promising solution, and the use of 2D bioprocess bags can help to streamline the manufacturing process and reduce costs. The 2D bioprocess bags market is also driven by technological advancements in bag design and materials. Manufacturers are developing bags with improved strength, durability, and resistance to punctures and leaks. In addition, there is a growing trend towards customization and scalability, with bags designed to meet specific requirements of different bioprocessing applications.
The 3D bioprocess bags segment is anticipated to grow at the fastest CAGR during the forecast period. They are commonly used in the production and storage of biologics, such as monoclonal antibodies, vaccines, and cell-based therapies. They provide a closed and sterile environment for cell culture, reducing the risk of contamination and ensuring the quality and consistency of the end product.The growing demand for regenerative medicine and increasing government funding for regenerative medicine is driving the growth of the industry. For instance, in 2021, The Regenerative Medicine Innovation Project (RMIP) was introduced in collaboration between the US National Institutes of Health (NIH) and the Food and Drug Administration (FDA) to support the development of safe and effective regenerative medicine products. The project aims to provide guidance to researchers and industry on best practices, develop new tools and standards for evaluating regenerative medicine products, and ensure that these products are developed with rigor to protect patient safety.
The upstream process segment held the highest market share of 43.76% in 2024. Bioprocessing bags are widely used in upstream processes for cell culture, media preparation, and fermentation. These bags provide a sterile and controlled environment for cell growth and are designed to optimize cell growth and productivity. They are available in various sizes and configurations, allowing for flexibility and scalability in upstream processes. The demand for bioprocessing bags in upstream processes is driven by several factors, including the increasing demand for biopharmaceuticals and vaccines, the shift towards single-use technologies, and the benefits of using disposable bags in terms of cost, efficiency, and risk reduction.
The downstream process is anticipated to register fastest CAGR during the forecast period. Bioprocess bags are widely used in the downstream process for storing and transporting the product during various stages of purification. They offer several advantages over traditional stainless steel vessels, including lower risk of contamination, reduced cleaning and validation requirements, and faster turnaround times. For instance, Sartorius AG offers Flexsafe bags, which are made from high-quality materials and are available in various sizes, ranging from 50 mL to 1,000 L. The bags are designed to be used with Sartorius' Flexboy and Flexboy Advance disposable bioreactors, providing a complete single-use solution for downstream bioprocessing.
The pharmaceutical & biopharmaceutical companies segment held the highest market share of 46.0% in 2024. The strategic activities adopted key market such as expansion, new product launch, merger & acquisition, and collaboration offer lucrative opportunities. For instance, in February 2021, Saint-Gobain announced launch of highly efficient cell culture bags for T-cell expansion. These new cell culture bags are designed to provide a sterile and controlled environment for the growth and expansion of T-cells, which are an essential component of the immune system and are used in cell-based therapies for the treatment of various diseases.
The CMOs & CROs segment is anticipated to register fastest CAGR over the forecast period. The adoption of contract services is being fueled by several benefits offered by CROs and CMOs, including scalability, flexibility, reduced internal infrastructure requirements, and dedicated supply channels. As a result, these advantages are expected to have a positive impact on the growth of the industry in the coming years. Also, the outsourcing of bioprocessing activities allows companies to focus on their core competencies, reduce costs, and improve efficiency. This trend has led to an increase in the number of CMOs and CROs, which, in turn, is expected to drive the growth of the market.
North America bioprocess bags market dominated the global market with a share of 35.65% in 2024. The increasing demand for biopharmaceuticals is expected to drive the growth of the bioprocess bags market in the region. Other factors that are expected to contribute to the growth of the bioprocess bags market in North America include the increasing adoption of single-use bioprocessing technologies and the growing focus on reducing the high costs associated with bioprocessing of advanced therapies. In addition, the presence of major biopharmaceutical companies and contract manufacturing organizations (CMOs) in North America is expected to drive the growth of the bioprocess bags market in the region. These companies require high-quality bioprocess bags for their operations.
U.S. Bioprocess Bags Market Trends
Strong investment in biopharmaceutical R&D and cell and gene therapy production is propelling demand for single-use bioprocess bags. The FDA’s proactive stance on advanced biologics manufacturing also supports the market's growth, with increased focus on modular, cost-effective manufacturing solutions.
Europe Bioprocess Bags Market Trends
The European bioprocess bags market benefits from widespread adoption of single-use technologies in biopharma facilities, particularly to meet environmental sustainability goals. The region’s emphasis on reducing carbon footprints and regulatory compliance in waste disposal further drives this shift toward single-use systems.
The UK’s vibrant biotech ecosystem, bolstered by government funding and initiatives like the Life Sciences Vision, emphasizes modular production techniques. This, alongside the focus on domestic biologics production due to Brexit, is enhancing the adoption of bioprocess bags.
France’s strong government support for the pharmaceutical sector, combined with increasing adoption of single-use bioprocessing to optimize production costs, is driving market demand. The country is focusing on strengthening its biologics and vaccine production capabilities, boosting the need for bioprocess bags.
Germany's highly developed biotech and pharmaceutical sector, which prioritizes efficient manufacturing processes, is spurring the demand for single-use bioprocess bags. Government incentives for innovation and environmental sustainability in production methods are further fostering market growth.
Asia Pacific Bioprocess Bags Market Trends
The Asia Pacific bioprocess bags market is estimated to be the fastest-growing region with CAGR due to the growing population, with increasing healthcare needs. As a result, there is a growing demand for biopharmaceuticals in the region, which is driving the growth of the bioprocess bags market. Another factor driving the growth of the bioprocess bags market in the Asia Pacific region is the increasing investment in the biopharmaceutical industry. Governments and private investors in countries like China, Japan, and South Korea are investing heavily in the biopharmaceutical industry, which is expected to drive the demand for bioprocess bags.
The China bioprocess bags market is expanding due to substantial investments in biopharma manufacturing and the local government’s support of biotech innovation. Demand is also fueled by the rapid scaling of biosimilars and biologics production to cater to domestic and global markets.
Japan bioprocess bags market is driven by technological advancements in the biotech sector and the country's push toward local biopharmaceutical production. In addition, Japan’s focus on efficient, cost-saving manufacturing practices is increasing the adoption of single-use systems.
MEA Bioprocess Bags Market Trends
Growth in the bioprocess bags market is supported by the expansion of pharmaceutical manufacturing in the region, with increased investment from global biotech companies establishing operations. A focus on healthcare infrastructure development is further propelling market interest.
Saudi Arabia’s Vision 2030 plan, aimed at diversifying the economy and boosting local pharmaceutical production, is driving demand for bioprocess bags. The country’s focus on improving healthcare standards and supporting local biotech manufacturing has spurred market growth.
In Kuwait, the demand for bioprocess bags is rising due to increased government investment in healthcare and efforts to develop local biopharma capabilities. The shift toward enhancing pharmaceutical production capabilities is expected to fuel bioprocess bag adoption in the coming years.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the bioprocess bags market
By Type
By Workflow
By End user
By Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Method
1.2.3. Application
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.9.1. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing demands for biopharmaceuticals
3.2.1.2. Advantages associated with implementation of single use technology in bio-manufacturing process
3.2.1.3. Rising outsourcing activities by CMOs and CROs
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory concerns due to leachable & extractable
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Bioprocess Bags Market: Type Business Analysis
4.1. Segment Dashboard
4.2. Bioprocess Bags Market: Type Market Share Analysis
4.3. Bioprocess Bags Market Estimates & Forecast, By Type (USD Million)
4.4. 2D Bioprocess Bags
4.4.1. Global 2D Bioprocess Bags Market, 2021 - 2034 (USD Million)
4.5. 3D Bioprocess Bags
4.5.1. Global 3D Bioprocess Bags Market, 2021 - 2034 (USD Million)
4.6. Other Bags & Accessories
4.6.1. Global Other Bags & Accessories Market, 2021 - 2034 (USD Million)
Chapter 5. Bioprocess Bags Market: Workflow Business Analysis
5.1. Segment Dashboard
5.2. Bioprocess Bags Market: Workflow Market Share Analysis
5.3. Bioprocess Bags Market Estimates & Forecast, By Workflow (USD Million)
5.4. Upstream Process
5.4.1. Global Upstream Process Market, 2021 - 2034 (USD Million)
5.5. Downstream Process
5.5.1. Global Downstream Process Market, 2021 - 2034 (USD Million)
5.6. Process Development
5.6.1. Global Process Development Market, 2021 - 2034 (USD Million)
Chapter 6. Bioprocess Bags Market: End user Business Analysis
6.1. Segment Dashboard
6.2. Bioprocess Bags Market: End user Market Share Analysis
6.3. Bioprocess Bags Market Estimates & Forecast, By End user (USD Million)
6.4. Pharmaceutical & Biopharmaceutical Companies
6.4.1. Global Pharmaceutical & Biopharmaceutical Companies Market, 2021 - 2034 (USD Million)
6.5. CMOs & CROs
6.5.1. Global CMOs & CROs Market, 2021 - 2034 (USD Million)
6.6. Academic & Research Institutes
6.6.1. Global Research Institutes Market, 2021 - 2034 (USD Million)
Chapter 7. Bioprocess Bags Market: Regional Estimates & Trend Analysis by Workflow, Product, End User
7.1. Bioprocess Bags Market Share By Region, 2024 & 2034
7.2. North America
7.2.1. North America Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.2.4. Mexico
7.2.4.1. Key Country Dynamics
7.2.4.2. Competitive Scenario
7.2.4.3. Regulatory Framework
7.2.4.4. Mexico Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3. Europe
7.3.1. Europe Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Denmark Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Sweden Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Norway Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. South Korea Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. Thailand Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.5. Latin America
7.5.1. Latin America Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.5.3. Argentina
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Argentina Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.6. MEA
7.6.1. MEA Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. UAE Bioprocess Bags Market, 2021 - 2034 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait Bioprocess Bags Market, 2021 - 2034 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Categorization
8.2. Company Market Position Analysis, 2024
8.3. Participant’s Overview
8.3.1. Thermo Fisher Scientific Inc.
8.3.1.1. Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Sartorius AG
8.3.2.1. Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Danaher Corporation
8.3.3.1. Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Merck KGaA
8.3.4.1. Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Saint Gobain
8.3.5.1. Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Corning Incorporated
8.3.6.1. Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Entegris
8.3.7.1. Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Meissner Filtration Products, Inc.
8.3.8.1. Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. PROAnalytics, LLC
8.3.9.1. Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. CellBios Healthcare And Lifesciences Pvt Ltd.
8.3.10.1. Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives